Biotech Analyst Pete Stavropoulos, PhD, moderated “Tackling Neurocognitive/Neurodegenerative Diseases – New Targets & Platforms.” The panel featured Arnon Rosenthal PhD, Co-Founder & CEO of Alector, Joe Payne, President & CEO of Arcturus Therapeutics, Mary Hamby, PhD, VP of Research at Cognition Therapeutics, Inc., Ryan Watts, CEO of Denali Therapeutics, and Matthias Alder, CEO of Gain Therapeutics.
• Discussions kicked off with the key consideration of picking the right patients for clinical trials, either through genetic stratification or identifying relevant biomarkers
• Subtypes of neurodegenerative diseases, particularly Alzheimer’s disease, are typically not well understood and unexpectedly heterogeneous when considering even one genetic mutation
• Biomarkers could help confirm whether the MoA of the drug translates into relevant therapeutic benefit and potential disease modification
• Towards the next 12-18 months, the panelists are looking forward to furthering the clinical development of their candidates with the use of biomarkers to demonstrate meaningful target engagement